Soghra Jarvandi
University of Glasgow
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Soghra Jarvandi.
Health and Quality of Life Outcomes | 2003
Ali Montazeri; Mariam Vahdaninia; Mandana Ebrahimi; Soghra Jarvandi
BackgroundThe Hospital Anxiety and Depression Scale (HADS) is a widely used instrument to measure psychological morbidity in cancer patients. This study aimed to translate and test the reliability and validity of the Iranian version of the HADS.MethodsThe English language version of the HADS was translated into Persian (Iranian language) and was used in this study. The questionnaire was administered to a consecutive sample of 167 breast cancer patients and statistical analysis was performed to test the reliability and validity of the HADS.ResultsIn general the Iranian version of the HADS was found to be acceptable to almost all patients (99%). Cronbachs alpha coefficient (to test reliability) has been found to be 0.78 for the HADS anxiety sub-scale and 0.86 for the HADS depression sub-scale. Validity as performed using known groups comparison analysis showed satisfactory results. Both anxiety and depression sub-scales discriminated well between sub-groups of patients differing in clinical status as defined by their disease stage.ConclusionThis preliminary validation study of the Iranian version of the HADS proved that it is an acceptable, a reliable and valid measure of psychological distress among cancer patients.
Supportive Care in Cancer | 1999
Ali Montazeri; Iraj Harirchi; Mariam Vahdani; Fatemeh Khaleghi; Soghra Jarvandi; Mandana Ebrahimi; Mehregan Haji-Mahmoodi
Abstract The objective of this study was to test the reliability and validity of the Iranian version of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30). The English-language version of the questionnaire was translated into Persian (Iranian language), and its final form was approved by the EORTC Study Group on Quality of Life before it was used in this study. The questionnaire was administered at two time points to a consecutive sample of 168 newly diagnosed breast cancer patients, and almost all of them (99%) found the questions easy to understand and acceptable. Crohnbachs alpha coefficient for multi-item scales (to test reliability) ranged from 0.48 to 0.95 at baseline and from 0.52 to 0.98 at follow-up administration of the questionnaire. Validity was checked using two methods: inter-scale correlation and known-groups comparison. Almost all inter-scale correlations were statistically significant in the expected direction. Known-groups comparison analysis showed that all functioning and symptom scales discriminated between subgroups of patients differing in clinical status as defined by their performance status and disease stage. In general, the findings of this study indicate that the Iranian version of the EORTC QLQ-C30 is a reliable and valid measure of quality of life in cancer patients and can be used in clinical trials and studies of outcome research in oncology.
European Journal of Cancer Prevention | 2010
Iraj Harirchi; Mojgan Karbakhsh; Ali Montazeri; Mandana Ebrahimi; Soghra Jarvandi; Neda Zamani; Amir-Javad Momtahen; Amir Kashefi; Mohammad-Reza Zafarghandi
The aim of this cross-sectional study was to show the characteristics of breast cancer across a period of 15 years according to pathological records in Tehran, Iran. In the year 1985, a 20-year study was designed and developed in five major hospitals in Tehran to study the burden and characteristics of breast cancer in Iran. This study is based on the data collected from 1986 through 2000. SPSS version 13 was used for statistical analysis. In this study, 1612 female breast cancer records were reviewed. The mean age of patients was 47.95±12.42 years with a median of 47 years. Over the study period, the proportion of tumors diagnosed at T2 increased with a decline in the proportion of T3 cases. Similarly, the percentage of stage II cases at diagnosis increased, whereas stage III decreased. We detected a decrease in tumor size and downstaging of female breast cancer in Tehran, Iran. This can be attributed to the overall improvement in the level of health in Iran and also educational activities that teach women how to perform breast self-exam and when and why to ask for breast examination.
Asia Pacific Family Medicine | 2008
Ali Montazeri; Mariam Vahdaninia; Iraj Harirchi; Amir Mahmood Harirchi; Akram Sajadian; Fatemeh Khaleghi; Mandana Ebrahimi; Shahpar Haghighat; Soghra Jarvandi
BMC Cancer | 2008
Ali Montazeri; Mariam Vahdaninia; Iraj Harirchi; Mandana Ebrahimi; Fatemeh Khaleghi; Soghra Jarvandi
Public Health | 2000
Iraj Harirchi; M Ebrahimi; N Zamani; Soghra Jarvandi; Ali Montazeri
Breast Journal | 2002
Mehregan Haji-Mahmoodi; Ali Montazeri; Soghra Jarvandi; Mandana Ebrahimi; Shahpar Haghighat; Iraj Harirchi
Patient Education and Counseling | 2001
Ali Montazeri; Soghra Jarvandi; Shahpar Haghighat; Mariam Vahdani; Akram Sajadian; Mandana Ebrahimi; Mehregan Haji-Mahmoodi
Public Health | 2002
Soghra Jarvandi; Ali Montazeri; Iraj Harirchi; A Kazemnejad
Quality of Life Research | 2000
Ali Montazeri; Iraj Harirchi; Mariam Vahdani; Fatemeh Khaleghi; Soghra Jarvandi; Mandana Ebrahimi; Mehregan Haji-Mahmoodi